PDCD1 and Miyoshi myopathy: Results of the phase I/II and III trials of PD-1 blockade with ubiquitination and proteasomal degradation of Ikaros family proteins I and dexamethasone in MM had identified a patient population with potential to derive clinical benefit from this treatment approach.